Percent mammographic density adjusted for age and body mass index (BMI) is one of the strongest risk factors for breast cancer and has a heritable component that remains largely unidentified. We performed a threestage genome-wide association study (GWAS) of percent mammographic density to identify novel genetic loci associated with this trait. In stage 1, we combined three GWASs of percent density comprised of 1241 *
INTRODUCTION
Percent mammographic density (PD) is an estimate of the proportion of stromal and epithelial breast tissues quantified from a mammogram image. Adjusted for age and body mass index (BMI), PD is one of the strongest risk factors for breast cancer, and women in the highest quartile of density have a 3 -5-fold increased risk compared with women in the lowest quartile (1) . Other known breast cancer risk factors, primarily BMI and age, are estimated to account for up to 20-30% of the variation in mammographic density (2, 3) . Twin and family studies suggest that up to two-thirds of the remaining variability are accounted for by genetic factors (4, 5) . Indeed, a recent genome-wide association study (GWAS) of PD adjusted for age and BMI identified a genome-wide significant association with a common genetic variant in the ZNF365 breast cancer susceptibility locus; there was evidence that the association between ZNF365 and breast cancer risk may be mediated through PD (6) . However, these single nucleotide polymorphisms (SNPs) are estimated to account for only 0.5-1.0% of the variance in adjusted PD, leaving much of the genetic contribution to this trait unexplained. We performed a three-stage GWAS to identify additional common genetic variation associated with the PD measure that predicts breast cancer risk.
RESULTS
We first evaluated associations between genome-wide SNPs and PD in a pooled analysis of three independent studies at the Mayo Clinic for which phenotype, risk factor and genomewide scan data were available (stage 1). These three studies collectively totaled 1241 women without breast cancer, involving 571 members of the Minnesota Breast Cancer Family Study (MBCFS), 317 controls from a case -control study of venous thromboembolism (Mayo VTE) and 363 controls from the Mayo Ovarian Cancer Case Control Study (MAY) (Supplementary Material, Tables S1 and S2), We analyzed SNPs that were either directly genotyped on the Illumina 660W Quad or 610 Quad arrays, or imputed using Phase II HapMap data on subjects of European ancestry (CEU) with an imputation quality score above 0.6 (Supplementary Material, Table S2 ). Demographic characteristics of the participants were similar across studies; all women were of European ancestry and the majority (74%) were post-menopausal at the time of mammogram (Supplementary Material, Tables S1 and S3). PD was measured by the same reader using the Cumulus software (7).
Overall, there was no evidence for genomic inflation among the directly genotyped (l ¼ 1.01) or imputed (l ¼ 1.00) SNPs in the analysis for association with PD adjusted for age and BMI (Supplementary Material, Figs S1 and S2). No SNPs achieved genome-wide significance (P , 5 × 10
28
) in the stage 1 analysis. We selected the top 99 SNPs representing 48 loci from the combined GWAS results, taking into account both overall significance and consistency of effect estimates across the three studies (Materials and Methods).
To replicate these findings, in stage 2, we evaluated the association between these 99 variants and PD adjusted for age and BMI in seven additional studies of PD in the Markers of Density (MODE) consortium comprised of 7018 women of European ancestry (stage 2: EPIC-Norfolk n ¼ 1142 controls; NHS Phase 1 n ¼ 1590 breast cancer cases and controls; NHS Phase 2 n ¼ 778 breast cancer cases and controls; SASBAC n ¼ 526 breast cancer cases; SASBAC n ¼ 742 controls; Toronto/Melbourne n ¼ 316 controls; SIBS n ¼ 1145 controls) (Supplementary Material, Tables S1, S3 and S4). Of the 99 SNPs, rs1265507 on chromosome12q24 had the strongest association with PD in stage 2 (P ¼ 2.74 × 10
25
). We then performed a meta-analysis of stage 1 and stage 2 data for these 99 SNPs (n ¼ 8269). As described previously (6), we combined P-values and the direction of association weighted by the square root of the sample size and studyspecific inflation factors, rather than combining effect estimates, due to differences in study design. In the combined analysis of studies from stages 1 and 2 (Supplementary Material, Table S5 ), a single SNP, rs1265507, displayed a genomewide significant association with PD adjusting for age and BMI (P ¼ 4.43 × 10
28
). The T allele of rs1265507 was inversely associated with PD in 9 of 10 studies (Table 1) . There was no evidence for heterogeneity of the association across studies (P heterogeneity ¼ 0.12).
To determine whether other SNPs in the region also demonstrated strong evidence for association with PD and to refine the region of association with PD on 12q24 particularly with respect to the nearby genes TBX3 and TBX5, we evaluated 459 additional variants at the 12q24 locus spanning a 407 kb region. These SNPs were selected to cover the nearby genes TBX5 and TBX3, including all SNPs that were either directly genotyped on the Illumina 660W Quad or 610 Quad arrays or imputed using Phase II HapMap data. Although these variants were previously examined in the stage 1 GWAS and few were selected for the replication, it is possible that some variants had stronger effects in the stage 2 or 3 studies. As such, we performed a meta-analysis for these 459 SNPs using data from 9126 samples from the three stage 1 GWAS studies, the seven stage 2 MODE studies and data from two additional studies (stage 3: Mayo Clinic PGRN n ¼ 213 breast cancer cases; MCBCS n ¼ 892 breast cancer cases, n ¼ 1,003 controls) (Supplementary Material, Tables S1, S2 and S4). In the combined analysis of stages 1, 2 and 3, rs1265507 remained the most significantly associated variant (P ¼ 1.03 × 10
) with no evidence for heterogeneity across studies (P heterogeneity ¼ 0.17) ( Table 1) . Exclusion of breast cancer cases from the rs1265507 analysis slightly attenuated the significance of the association (P ¼ 2.98 × 10 28 ) (Supplementary Material, Table S6 ). An additional 39 variants in moderate to strong LD with rs1265507 in a 33.2 kb region surrounding rs1265507 were also associated with PD (P , 5 × 10 24 ) (Fig. 1 , Supplementary Material, Table S7 ). Of these, rs2551389 was in perfect LD with rs1265507 (R 2 ¼ 1) and also achieved genome-wide signifi- Table S8 ). We also found that these two 12q24 SNPs were associated with absolute dense area, with some attenuation of significance compared with the PD result [rs1265507 P ¼ 6.61 × 10 Tables S9 and S10 ). Across studies with genotype data for rs1265507 (excluding the Toronto/Melbourne study), rs1265507 was associated with a mean change of 21.03% in PD per copy of the minor allele. Based on this estimate, rs1265507 would explain at most 1.3% of the variance in percent mammographic density.
Given that age-and BMI-adjusted mammographic density is a strong risk factor for breast cancer and that variants from 12q24 over 250 kb distal to rs1265507 have recently shown genome-wide significant associations with breast cancer (8), we evaluated whether rs1265507 was associated with the risk of breast cancer in MCBCS, SASBAC, the Cancer Genetic Markers of Susceptibility (CGEMS) study (9) and the UK2 GWAS (10) (Supplementary Methods, Supplementary Material, Table S11 ). No significant evidence for association with breast cancer was observed [combined odds ratio (OR) ¼ 0.99, 95% confidence interval (CI) 0.95 -1.04, P ¼ 0.67] (Supplementary Material, Table S12 ), suggesting that any causal variants underlying the association between rs1265507 and adjusted PD are not strong independent risk factors for breast cancer. However, it remains possible that variants underlying the independent mammographic density and breast cancer associations have common biological effects in this region. 
DISCUSSION
Through a three-stage GWAS, we describe a novel genomewide significant association between rs1265507 at 12q24 and PD adjusting for age and BMI (P ¼ 1.03 × 10
28
). We further demonstrate that this SNP had the strongest association of those examined in the 12q24 region, and was located in a cluster of SNPs surrounding rs1265507 also associated with PD (P , 5 × 10 24 ). This is only the second genetic locus identified for age-and BMI-adjusted PD to date.
Rs1265507 is located 22 kb from the 5 ′ untranslated region (UTR) of the T-box 5 (TBX5) gene and 240 kb from the 3 ′ UTR of the T-box 3 (TBX3) gene. TBX5 and TBX3 are both members of the phylogenetically conserved T-box gene family, which encode transcription factors involved in developmental regulation. Interestingly, the cluster of 39 SNPs most strongly associated with age-and BMI-adjusted PD surrounding rs1265507 appears to be located in a region flanked by the coding region of TBX5 and a recombination hotspot (recombination rate 60 cM/Mb) (Fig. 1) . This raises the possibility that the underlying causal variant(s) influence the regulation of the TBX5 promoter. While rs1265507 was not associated with expression of either TBX5 or TBX3 as reported in two databases of expression quantitative trait loci (eQTL), the Wellcome Trust Genevar database and the University of Chicago eQTL browser (11, 12) , these databases did not include expression data from normal breast epithelium or stromal tissue. Mutations in TBX5 are associated with Holt-Oram syndrome, a developmental disorder affecting the heart and upper limbs (13) . TBX5 has also recently been implicated as a tumor suppressor gene that is epigenetically inactivated in colon cancer (14) . In addition, TBX3 has been implicated in embryonic development of the mammary gland (15, 16) , and mutations in this gene have been linked to ulnar-mammary syndrome (17) . TBX3 is also overexpressed in breast tumors (18) , and a recent study using an inducible transgenic mouse model showed that TBX3 overexpression induces mammary gland hyperplasia and increases mammary stem-like cells (19) .
We recognize that the design of participant studies used for this GWAS varied, including the use of different mammography views and genotyping platforms. However, the consistency of association across studies supports the validity of this finding. Additionally, a strength of this study is that a single reader estimated PD for the stage 1 studies, thereby reducing noise in our density phenotype and increasing our power to detect genetic associations with PD. Also, our increased sample size from the original MODE GWAS (6) (8269 in stages 1 -2 compared with 4877 in MODE), coupled with a more homogenous density phenotype in stage 1, resulted in the identification and confirmation of the 12q24 locus. The use of imputed genotype data in our replication and finemapping analyses may have affected the estimated strength of association for all variants, and precluded our ability to detect genome-wide significance for some variants; however, GWAS studies of mammographic density measures with larger sample sizes will help to clarify these associations and to identify additional common variants associated with this trait. This is only the second genetic locus identified for age-and BMI-adjusted PD, and unlike the ZNF365 locus (6), does not appear to be associated with breast cancer risk. As we learned from this association between PD and the ZNF365 locus, the identification of genetic associations with PD may correspond to known or novel breast cancer risk loci due to the strong relationship between mammographic density and breast cancer risk. However, although age-and BMI-adjusted percent mammographic density is a predictor of breast cancer risk, the majority of women with high breast density never develop breast cancer. It may be important to identify genetic factors that are not related to breast cancer risk to aid in discriminating between biological pathways that are crucial to breast tumorigenesis in dense breast tissue and those that are not. This, in turn, may help explain why only a portion of women with high breast density eventually develop breast cancer. In addition, newly identified genetic variation associated with density could lead to improved methods for visualization of cancers in dense tissue. This could include the development of new pharmaceutical agents for decreasing dense tissue in a woman to allow better screening for breast cancer or even new technologies relating to better imaging of dense tissue.
This study provides additional evidence that common genetic variation contributes to breast tissue composition. Resequencing, fine-mapping and functional studies of the 12q24 locus in additional studies of mammographic density are necessary to understand the causal variants and mechanism underlying this novel association.
MATERIALS AND METHODS

Mayo Clinic GWAS studies
Three independent studies at the Mayo Clinic (Rochester, MN, USA) contributed genotype and phenotype data to the stage 1 GWAS and meta-analyses. Women of white European ancestry with GWAS and density data were included from the Minnesota Breast Cancer Family Study (MBCFS n ¼ 571 controls), the Mayo Venous Thromboembolism Study (Mayo VTE n ¼ 317 controls) and the Mayo Clinic Ovarian Case Control Study (MAY n ¼ 363 controls). These studies are described in detail in Supplementary Material.
MODE studies
Seven independent studies from the Markers of Density (MODE) consortium contributed summary statistics from analyses of associations between stage 2 (n ¼ 99) and stage 3 (n ¼ 459) SNPs and adjusted PD. These studies were comprised of EPIC-Norfolk (n ¼ 1142 controls), the Nurses' Health Study (NHS Phase 1 n ¼ 1590 breast cancer cases and controls; Phase 2 n ¼ 778 breast cancer cases and controls), the Singapore and Sweden Breast Cancer Study (SASBAC n ¼ 526 breast cancer cases; n ¼ 742 controls), the Toronto/Melbourne study (n ¼ 316 controls) and the Sisters in Breast Screening study (SIBS n ¼ 1145 controls). All MODE studies were comprised of women of self-reported European ancestry. These studies are also described in detail in Supplementary Material.
Additional chromosome 12 fine-mapping studies
Two additional, independent studies from the Mayo Clinic contributed data to the Stage 3 meta-analysis of the 459 SNPs on chromosome 12q24. These included the Mayo Pharmacogenetics Research Network Aromatase Inhibitor (AI) Study (Mayo PGRN n ¼ 213 breast cancer cases) and the Mayo Clinic Breast Cancer Study (MCBCS n ¼ 892 breast cancer cases, n ¼ 1003 controls). The Mayo PGRN and MCBCS contained only women of white European ancestry and are also described in detail in Supplementary Material.
Percent mammographic density measurement
Mammogram collection and estimation of percent density are described for each study in Supplementary Material. Percent density was measured from mammograms using the craniocaudal view, the mediolateral-oblique view or the average of the two views using the Cumulus software (7) (Supplementary Material, Table S2 ).
Stage 1: GWAS genotyping, imputation and analyses
MBCFS and MAY samples were genotyped at the Mayo Clinic Genotyping Shared Resource on the Illumina HumanHap 660W Quad and Illumina 610K arrays, respectively. Mayo VTE genotyping was performed as part of a larger GWAS of VTE using the Illumina 660W Quad array at the Center for Inherited Disease Research at Johns Hopkins University. Prior to sample exclusions, there were 597 MBCFS, 427 MAY and 638 Mayo VTE samples for a total of 1662 genotyped samples available for the pooled GWAS analysis. Samples were excluded for the following reasons: call rates , 98% (n ¼ 31), duplicates across the studies (n ¼ 21) and gender (n ¼ 4) (Supplementary Material, Table S2 ). Genotype data for the remaining 1625 women were combined using Plink. All failed SNPs, monomorphic SNPs and SNPs with call rates , 95% were excluded, resulting in 521 571 SNPs in the combined Mayo GWAS data set. MACH version 1.0.16 was used to impute autosomal SNPs for the remaining 1625 samples using the Hapmap II build 36 CEU reference population. A total of 2 510 880 SNPs with R 2 . 0.6 or MAF . 1% were retained for the analysis. After imputation, we then excluded samples that were possibly related (n ¼ 3), non-European (n ¼ 1), VTE cases (n ¼ 167) and those that did not have complete phenotype and covariate data (n ¼ 190), leaving a total of 1241 samples for analysis.
The final analytic data set contained 1241 women with complete mammographic density, covariate and genotype data: 571 MBCFS, 313 Mayo VTE and 357 MAY. Information on 1942 additional MBCFS family members without phenotype data were used to inform family structure for analyses. Linear mixed-effects models were fit to test the additive association of genotype with square root percent density after adjusting for age, BMI, menopausal status and study while also accounting for genetic relatedness among individuals through the incorporation of a polygenic random effect into the model. We assessed the degree to which population stratification influenced our results by adjusting for the first two principal components (PC) from a PC analysis utilizing ancestry informative markers. Inclusion of these PCs did not affect the results of the analysis and suggested that population stratification is minimal. These analyses were performed in the multic package in R (http://cran.r-project.org/).
SNP selection for replication
We selected SNPs from stage 1 for replication using the following method. First, we considered overall significance of SNP associations in the pooled stage 1 analysis, and selected SNPs in order of P-value rank. We retained these SNPs if they were associated with PD in the same direction in at least two of the three stage 1 studies; had a HWE P . 0.001; and if imputed (rather than genotyped), had an imputation quality score (R 2 ) . 0.8. Additional SNPs from the same locus were included for replication in the following situations: (i) additional SNPs in the region had P-values , 0.01 or (ii) if the most significant SNPs in the locus was imputed, the genotyped SNP with the lowest P-value and highest LD was also included for replication. SNPs from the same locus were not filtered to be in low pair-wise LD with each other.
Stages 2 and 3: genotyping, imputation and analyses
The individual MODE studies were genotyped on multiple platforms and used various quality control assessments (Supplementary Material, Table S4 ). All MODE studies used identical-by-state or identical-by-descent measurements to identify and exclude individuals with unexpected relatedness. Since the SASBAC genotyped their breast cancer cases and controls on separate platforms, they were imputed and analyzed separately. All studies, other than Mayo PGRN and MCBCS, performed imputation to obtain a total of 2.5 million autosomal genotypes using HapMap Phase II CEU samples as reference. To reassure high-quality data for all studies, we excluded all SNPs with a minor allele frequency below 0.01 or an imputation quality score below 0.6 [as defined by the RSQR_HAT value in MACH (20, 21) , the PROPER_INFO in IMPUTE (22, 23) and the information content (INFO) measure in PLINK (http://pngu.mgh.harvard. edu/purcell/plink/) (24) ]. Study-specific summary estimates from linear regression analyses of square root PD (see Supplementary Material, Table S4 ) were obtained for the 99 and 459 SNPs of interest in stages 2 and 3, respectively. All studies were adjusted for age and BMI; NHS, SASBAC and the Toronto/Melbourne study adjusted for population stratification using principal components analysis. Additional study-specific adjustments are described in Supplementary Material, Table S4 .
Mayo PGRN subjects who provided blood samples as a source of DNA (n ¼ 835) were genotyped using the Illumina 610K array, performed at RIKEN, with 830 cases passing genotype quality control. One hundred four genotyped SNPs of the 459 SNPs of interest in the 12q24 region were analyzed for association with the square root of PD adjusted for age, BMI, menopausal status and breast cancer case -control status.
Genotyping of the rs1265507 SNP in MCBCS was performed using a TaqMan assay at the Mayo Clinic Genotyping Shared Resource. A total of 95 CEPH controls on a Coriell test plate, HAPMAPPT01, were also typed simultaneously to establish genotyping accuracy. Genotyping of the rs1265507 SNP displayed high SNP call rates (≥99% for cases, controls and overall), high concordant rate (100%) and no deviation from Hardy -Weinberg equilibrium among controls (P ¼ 0.52). Rs1265507 was analyzed for association with square root of PD adjusting for age, BMI and menopausal status.
Meta-analyses
All meta-analyses were based on summary statistics from contributing studies. The study-specific summary statistics obtained were sample size, alleles tested, minor allele frequency, effect estimate (b), standard error and P-value. For each SNP, we combined study-specific P-values and direction of association using the METAL software (25) . Weights were proportional to study-specific sample size and P-values were adjusted with genomic inflation factors, where relevant. To account for the extreme sampling scheme in the Toronto/Melbourne study, we up-weighted this study with a scale factor of 3.51. The scale factor was determined as described by Lindstrom et al. (6) . We used Cochran's Q statistic to test for heterogeneity across studies.
The meta-analysis of the top 48 loci from the Mayo Clinic GWAS for stage 1 and 2 combined was based on summary statistics for 99 SNPs (Supplementary Material, Table S4 ) from 10 studies in a total of up to 8283 Caucasian women. Studies included in this analysis were the three Mayo Clinic GWAS and the seven Markers of Density (MODE) studies (SASBAC cases and controls separately, EPIC-Norfolk, NHS phases 1 and 2 separately, Toronto/Melbourne, SIBS). Analyses of each study-specific MODE GWAS from which these estimates were obtained have been described previously (6) . Briefly, similar to above, the square root of PD was used as the outcome, adjusting for age, BMI, menopausal status and case-control status, when applicable.
Meta-analysis of 459 chromosome 12q24.21 fine-mapping SNPs was based on summary statistics from 11 studies in a total of up to 10 377 Caucasian women. Studies included in this analysis were the three Mayo Clinic GWAS, the seven MODE studies, Mayo PGRN and MCBCS. The Mayo PGRN study contributed data only for those 104 SNPs which were directly genotyped on the Illumina 610K platform. The final rs1265507 combined analyses of all studies (stages 1 -3) were performed using summary statistics from the three Mayo Clinic GWAS studies, seven MODE studies, Mayo PGRN and MCBCS. Figure 1 was generated using the LocuzZoom tool (26) .
Association with breast cancer
The association between rs1265507 and risk of breast cancer was examined in MCBCS, SASBAC, the Cancer Genetic Markers of Susceptibility study (CGEMS) (9) and a GWAS of breast cancer in the UK (UK2 GWAS) (10) . The odds ratio, 95% confidence interval and P-value for the rs1265507 association with breast cancer in CGEMS were obtained using publically available data. For MCBCS, SASBAC and the UK2 GWAS, analyses were conducted using logistic regression. MCBCS adjusted for age, 1/BMI, menopausal status and SASBAC adjusted for three principal components, age, BMI and menopausal status. The UK2 GWAS adjusted for two principal components. A combined estimate was calculated using the metagen function in the 'meta' R package (http://cran.r-project.org/).
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